Complete regression of a previously untreated melanoma brain metastasis with ipilimumab

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

2008 • 639 citations

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

2007 • 612 citations

Immunostimulatory monoclonal antibodies for cancer therapy

2007 • 596 citations

Checkpoint Blockade in Cancer Immunotherapy

2006 • 558 citations

Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment

2005 • 534 citations

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

2006 • 437 citations

Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients

2008 • 286 citations

Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.

1996 • 209 citations

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS

2008 • 164 citations

Technology evaluation: ipilimumab, Medarex/Bristol-Myers Squibb.

2005 • 48 citations

Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study

2008 • 47 citations

Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody

2008 • 36 citations

Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies

2008 • 36 citations

An analysis of the effectiveness of specific guidelines for the management of ipilimumab-mediated diarrhea/colitis: Prevention of gastrointestinal perforation and/or colectomy

2008 • 36 citations

Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials

2009 • 23 citations

Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide

2008 • 11 citations

EFFECT OF DOSE ON EFFICACY AND SAFETY IN IPILIMUMAB-TREATED PATIENTS WITH ADVANCED MELANOMA - RESULTS FROM A PHASE II, RANDOMIZED, DOSE-RANGING STUDY

2008 • 10 citations

Moving forward with immunotherapy: the rationale for anti-CTLA-4 therapy in melanoma

2008 • 6 citations